SignalCorporate
Regeneron Q3 revenue tops estimates on Sanofi Dupixent profit; shares rise 4%
Regeneron Q3 revenue beat estimates on Sanofi Dupixent profit, lifting shares 4%.
Context
What happened: Regeneron (NASDAQ:REGN) reported third-quarter profit and revenue above Wall Street estimates, driven by higher Sanofi Dupixent payments while Eylea sales kept sliding. Shares rose 4% in premarket trading.
Key numbers: Adjusted EPS $20.07 vs $16.06 expected.
Why it matters: Regeneron raised its 2026 adjusted R&D expense forecast and its adjusted gross margin outlook to about 86%, while lowering its SG&A outlook. CEO Leonard Schleifer called it an outstanding quarter, with Dupixent, Eylea HD and Libtayo each at record net sales.
Market: +0.7% today ($818.77), +5.8% YTD, 1.1x vol — as of 13:15 UTC
Verified: Q3_2026 (Oct 30) EPS $20.07 vs $16.25 est, +23.5% beat; next print ~Jan 29
Coverage: 4 outlets in 24h
What changed
Regeneron (NASDAQ:REGN) reported third-quarter profit and revenue above Wall Street estimates, driven by higher Sanofi Dupixent payments while Eylea sales kept sliding. Shares rose 4% in premarket trading.
Why it matters
Regeneron raised its 2026 adjusted R&D expense forecast and its adjusted gross margin outlook to about 86%, while lowering its SG&A outlook. CEO Leonard Schleifer called it an outstanding quarter, with Dupixent, Eylea HD and Libtayo each at record net sales.
Market: +0.7% today ($818.77), +5.8% YTD, 1.1x vol — as of 13:15 UTC
Verified: Q3_2026 (Oct 30) EPS $20.07 vs $16.25 est, +23.5% beat; next print ~Jan 29